Cargando…

Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)

BACKGROUND: The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN....

Descripción completa

Detalles Bibliográficos
Autores principales: Baselga-Moreno, Víctor, Trushakova, Svetlana, McNeil, Shelly, Sominina, Anna, Nunes, Marta C., Draganescu, Anca, Unal, Serhat, Koul, Parvaiz, Kyncl, Jan, Zhang, Tao, Kuatbayeva, Ainagul, Ben-Salah, Afif, Burtseva, Elena, Puig-Barberà, Joan, Díez-Domingo, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498567/
https://www.ncbi.nlm.nih.gov/pubmed/31046725
http://dx.doi.org/10.1186/s12889-019-6713-5
_version_ 1783415637715976192
author Baselga-Moreno, Víctor
Trushakova, Svetlana
McNeil, Shelly
Sominina, Anna
Nunes, Marta C.
Draganescu, Anca
Unal, Serhat
Koul, Parvaiz
Kyncl, Jan
Zhang, Tao
Kuatbayeva, Ainagul
Ben-Salah, Afif
Burtseva, Elena
Puig-Barberà, Joan
Díez-Domingo, Javier
author_facet Baselga-Moreno, Víctor
Trushakova, Svetlana
McNeil, Shelly
Sominina, Anna
Nunes, Marta C.
Draganescu, Anca
Unal, Serhat
Koul, Parvaiz
Kyncl, Jan
Zhang, Tao
Kuatbayeva, Ainagul
Ben-Salah, Afif
Burtseva, Elena
Puig-Barberà, Joan
Díez-Domingo, Javier
author_sort Baselga-Moreno, Víctor
collection PubMed
description BACKGROUND: The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN. In the 2016–2017 influenza season, 15 sites in 14 countries participated in the GIHSN, although the analyses could not be performed in 2 sites. A common core protocol was used in order to make results comparable. Here we present the results of the GIHSN 2016–2017 influenza season. METHODS: A RT-PCR test was performed to all patients that accomplished the requirements detailed on a common core protocol. Patients admitted were included in the study after signing the informed consent, if they were residents, not institutionalised, not discharged in the previous 30 days from other hospitalisation with symptoms onset within the 7 days prior to admission. Patients 5 years old or more must also complied the Influenza-Like Illness definition. A test negative-design was implemented to perform IVE analysis. IVE was estimated using a logistic regression model, with the formula IVE = (1-aOR) × 100, where aOR is the adjusted Odds Ratio comparing cases and controls. RESULTS: Among 21,967 screened patients, 10,140 (46.16%) were included, as they accomplished the inclusion criteria, and tested, and therefore 11,827 (53.84%) patients were excluded. Around 60% of all patients included with laboratory results were recruited at 3 sites. The predominant strain was A(H3N2), detected in 63.6% of the cases (1840 patients), followed by B/Victoria, in 21.3% of the cases (618 patients). There were 2895 influenza positive patients (28.6% of the included patients). A(H1N1)pdm09 strain was mainly found in Mexico. IVE could only be performed in 6 sites separately. Overall IVE was 27.24 (95% CI 15.62–37.27. Vaccination seemed to confer better protection against influenza B and in people 2–4 years, or 85 years old or older. The aOR for hospitalized and testing positive for influenza was 3.02 (95% CI 1.59–5.76) comparing pregnant with non-pregnant women. CONCLUSIONS: Vaccination prevented around 1 in 4 hospitalisations with influenza. Sparse numbers didn’t allow estimating IVE in all sites separately. Pregnancy was found a risk factor for influenza, having 3 times more risk of being admitted with influenza for pregnant women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12889-019-6713-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6498567
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64985672019-05-09 Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) Baselga-Moreno, Víctor Trushakova, Svetlana McNeil, Shelly Sominina, Anna Nunes, Marta C. Draganescu, Anca Unal, Serhat Koul, Parvaiz Kyncl, Jan Zhang, Tao Kuatbayeva, Ainagul Ben-Salah, Afif Burtseva, Elena Puig-Barberà, Joan Díez-Domingo, Javier BMC Public Health Research Article BACKGROUND: The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN. In the 2016–2017 influenza season, 15 sites in 14 countries participated in the GIHSN, although the analyses could not be performed in 2 sites. A common core protocol was used in order to make results comparable. Here we present the results of the GIHSN 2016–2017 influenza season. METHODS: A RT-PCR test was performed to all patients that accomplished the requirements detailed on a common core protocol. Patients admitted were included in the study after signing the informed consent, if they were residents, not institutionalised, not discharged in the previous 30 days from other hospitalisation with symptoms onset within the 7 days prior to admission. Patients 5 years old or more must also complied the Influenza-Like Illness definition. A test negative-design was implemented to perform IVE analysis. IVE was estimated using a logistic regression model, with the formula IVE = (1-aOR) × 100, where aOR is the adjusted Odds Ratio comparing cases and controls. RESULTS: Among 21,967 screened patients, 10,140 (46.16%) were included, as they accomplished the inclusion criteria, and tested, and therefore 11,827 (53.84%) patients were excluded. Around 60% of all patients included with laboratory results were recruited at 3 sites. The predominant strain was A(H3N2), detected in 63.6% of the cases (1840 patients), followed by B/Victoria, in 21.3% of the cases (618 patients). There were 2895 influenza positive patients (28.6% of the included patients). A(H1N1)pdm09 strain was mainly found in Mexico. IVE could only be performed in 6 sites separately. Overall IVE was 27.24 (95% CI 15.62–37.27. Vaccination seemed to confer better protection against influenza B and in people 2–4 years, or 85 years old or older. The aOR for hospitalized and testing positive for influenza was 3.02 (95% CI 1.59–5.76) comparing pregnant with non-pregnant women. CONCLUSIONS: Vaccination prevented around 1 in 4 hospitalisations with influenza. Sparse numbers didn’t allow estimating IVE in all sites separately. Pregnancy was found a risk factor for influenza, having 3 times more risk of being admitted with influenza for pregnant women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12889-019-6713-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-02 /pmc/articles/PMC6498567/ /pubmed/31046725 http://dx.doi.org/10.1186/s12889-019-6713-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Baselga-Moreno, Víctor
Trushakova, Svetlana
McNeil, Shelly
Sominina, Anna
Nunes, Marta C.
Draganescu, Anca
Unal, Serhat
Koul, Parvaiz
Kyncl, Jan
Zhang, Tao
Kuatbayeva, Ainagul
Ben-Salah, Afif
Burtseva, Elena
Puig-Barberà, Joan
Díez-Domingo, Javier
Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
title Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
title_full Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
title_fullStr Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
title_full_unstemmed Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
title_short Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
title_sort influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the global influenza hospital surveillance network (gihsn)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498567/
https://www.ncbi.nlm.nih.gov/pubmed/31046725
http://dx.doi.org/10.1186/s12889-019-6713-5
work_keys_str_mv AT baselgamorenovictor influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT trushakovasvetlana influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT mcneilshelly influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT somininaanna influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT nunesmartac influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT draganescuanca influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT unalserhat influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT koulparvaiz influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT kyncljan influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT zhangtao influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT kuatbayevaainagul influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT bensalahafif influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT burtsevaelena influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT puigbarberajoan influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT diezdomingojavier influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn
AT influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn